KOD Kodiak Sciences Inc.

Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.

Investing.com -- B. Riley Securities reiterated its Buy rating and $37 price target on 4D Molecular Therapeutics, citing the launch of a Phase 3 trial in diabetic macular edema and encouraging two-year data for its lead gene therapy candidate.

Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.

Regeneron Pharmaceuticals (NasdaqGS: REGN) faces fresh pressure after Kodiak Sciences reported new Phase 3 data on its eye drugs. Kodiak said Zenkuda and tabirafusp alfa tedromer matched Eylea on primary Phase 3 endpoints for macular degeneration treatment. The trial reported similar vision outcomes with Kodiak's candidates given roughly every six months versus Eylea's current eight week dosing interval. This comparison between Eylea and Kodiak's longer interval injections is only one piece...

Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.

Its latest study suggested its drug candidates improved eyesight for patients with wet macular degeneration as much as the leading treatment.

The biotech is developing innovative therapies for people with eye diseases.

Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.

Kodiak Sciences Inc. (NASDAQ:KOD) saw its share price nearly triple on Monday to a near five-year high, as investors loaded positions to cheer strong clinical trial results for its wet AMD treatment candidate. In intraday trading, the stock soared by as much as 196 percent before trimming gains to finish the session just up by […]

FEATURE Stocks fell Monday as waning peace talks between the U.S. and Iran drove oil prices and bond yields higher. Nvidia rose 1.7%. The chip maker said it would launch the largest-ever U.S. stock buyback of $150 billion, bringing the total buyback authorization to $235 billion.

(Updates with index/price action, macroeconomic data, corporate developments, company/geopolitical n

Kodiak Sciences recently highlighted that it is on track to report top-line Phase III DAYBREAK results for Zenkuda (tarcocimab tedromer) and KSI-501 in treatment-naïve wet age-related macular degeneration, part of a broader push into retinal vascular diseases that it views as a roughly US$15.00 billion anti-VEGF market. The company’s additional late-stage programs, including the PEAK and PINNACLE trials in macular edema and the ALTO study of KSI-501 in diabetic macular edema, position its...

Kodiak Sciences has seen its share price move sharply in recent years, which puts a spotlight on whether the current US$31.52 level is supported by the company’s book value. With that kind of price action, the key issue for you is how much of Kodiak Sciences’ balance sheet strength is already reflected in today’s valuation. Over the past 3 years the stock has delivered a very large gain of about 15x. As a result, any discussion of value now needs to start with how much balance sheet support...

Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.

KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.

Kodiak Sciences, Capricor Therapeutics and Invivyd each face pivotal clinical trial or FDA decisions before the end of 2026 that could significantly move their stock prices.

On August 13, Kodiak Sciences Inc. (NASDAQ:KOD) reported second-quarter financial results for the period ended June 30, alongside an update on its three late-stage eye disease programs. The clinical-stage biotech told investors it now sits within months of three separate Phase 3 readouts, a stretch CEO Victor Perlroth called the payoff of years of disciplined […]

KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.

Kodiak launches a global phase III study of KSI-501 in DME, testing its dual IL-6 and VEGF approach for durable disease control.